Related Experiment Video
Updated: Aug 4, 2026
09:17
High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation
Published on: July 29, 2011
beta(2)-Adrenoceptors and ventricular fibrillation
1Department of Medical Biochemistry, The Ohio State University College of Medicine and Public Health, 333 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210-1218, USA.Altschund.2@osu.edu
Pharmacology & Therapeutics
|October 18, 2000
Summary
Beta-blockers reduce sudden cardiac death by targeting beta-adrenoceptors. Selective beta(2)-adrenoceptor blockade prevents fatal arrhythmias, offering a new therapeutic strategy for contractile dysfunction.
Area of Science:
- Cardiology
- Molecular Pharmacology
Background:
- Contractile dysfunction involves altered beta-adrenoceptor (β-AR) signaling, with decreased β(1)-AR and unchanged β(2)-AR levels.
- Increased responsiveness to β(2)-AR stimulation is observed in contractile dysfunction.
Purpose of the Study:
- To investigate the role of β(2)-AR in sudden cardiac death and ventricular fibrillation.
- To explore the mechanisms underlying β(2)-AR-mediated arrhythmogenesis.
Main Methods:
- Utilized a canine model of sudden cardiac death.
- Examined the effects of selective β(2)-AR blockade on ventricular fibrillation.
- Assessed cardiac ion currents and intracellular calcium handling.
Main Results:
- Selective β(2)-AR blockade prevented ventricular fibrillation in a cardiac dysfunction model.
- β(2)-AR stimulation increased L-type Ca(2+) currents but did not phosphorylate phospholamban.
- Enhanced Ca(2+) influx via β(2)-AR relies on Na(+)/Ca(2+) exchange, promoting arrhythmogenic currents.
Conclusions:
- Targeting β(2)-AR offers a novel approach to prevent sudden cardiac death in patients with contractile dysfunction.
- The arrhythmogenic potential of β(2)-AR stimulation is linked to Na(+)/Ca(2+) exchange activity.
Related Concept Videos
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...